Royalty Pharma expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,375 million and $2,475 million, excluding a potential $475 million milestone related to FDA approval of intranasal zavegepant and transactions announced subsequent to the date of this release. This guidance represents underlying growth of 4% to 9% prior to payments related to the Biohaven Preferred Shares in 2022.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RPRX:
- Royalty Pharma Reports Q4 and Full Year 2022 Results
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
- Royalty Pharma provides business update, outlook
- Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
